Abstract:Adipose‐derived stromal vascular fraction (SVF) is an emerging autologous cellular therapeutic which mediates repair through 'bi‐directional' communication in response to pathological cues. SVF maintains a high safety index in pre‐clinical and clinical investigations of multiple sclerosis, Alzheimer's disease and Parkinson's disease. Pre‐clinical evidence suggests that SVF modulates the inflammatory response via macrophage and T‐cell polarization locally and systemically. SVF‐treated groups result in significantly better outcomes compared toits purified and cultured mesenchymal stromal cell/adipose stem cell counterpart, improving behavior and disease severity at early intervention time‐points. Outcomes of SVF cellular therapy is dependent on SVF composition, which widely differs from patient to patient. Neurodegenerative disorders are characterized by the gradual decline and irreversible loss of cognitive functions and CNS structures. As therapeutic recourse stagnates, neurodegenerative diseases will cost over a trillion dollars by 2050. A dearth of preventive and regenerative measures to hinder regression and enhance recovery has forced patients to settle for traditional therapeutics designed to manage symptoms, leaving little hope for a cure. In the last decade, pre‐clinical animal models and clinical investigations in humans have demonstrated the safety and promise of an emerging cellular product from subcutaneous fat. The adipose‐derived stromal vascular fraction (SVF) is an early intervention and late‐stage novel 'at point' of care cellular treatment, demonstrating improvements in clinical applications for Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease. SVF is a heterogeneous fraction of cells forming a robust cellular ecosystem and serving as a novel and valuable source of point‐of‐care autologous cell therapy, providing an easy‐to‐access population that we hypothesize can mediate repair through 'bi‐directional' communication in response to pathological cues. We provide the first comprehensive review of all pre‐clinical and clinical findings available to date and highlight major challenges and future directions. There is a greater medical and economic urgency to innovate and develop novel cellular therapy solutions that enable the repair and regeneration of neuronal tissue that has undergone irreversible and permanent damage.

Emerging point‐of‐care autologous cellular therapy using adipose‐derived stromal vascular fraction for neurodegenerative diseases